Herb-drug pharmacokinetic interaction between carica papaya extract and amiodarone in rats.

PURPOSE Carica papaya has been traditionally used worldwide in folk medicine to treat a wide range of ailments in humans, including the management of obesity and digestive disorders. However, scientific information about its potential to interact with conventional drugs is lacking. Thus, this work aimed to investigate the interference of a standardized C. papaya extract (GMP certificate) on the systemic exposure to amiodarone (a narrow therapeutic index drug) in rats. METHODS In the first pharmacokinetic study, rats were simultaneously co-administered with a single-dose of C. papaya (1230 mg/kg, p.o.) and amiodarone (50 mg/kg, p.o.); in the second study, rats were pre-treated for 14 days with C. papaya (1230 mg/kg/day, p.o.) and received amiodarone (50 mg/kg, p.o.) on the 15th day. Rats of the control groups received the herbal extract vehicle. Blood samples were collected before dosing and at 0.25, 0.5, 1, 2, 4, 6, 8 and 12 h following amiodarone administration; in addition, at 24 h post-dose, blood and tissues (heart, liver, kidneys and lungs) were also harvested. Thereafter, the concentrations of amiodarone and its major metabolite (mono-N-desethylamiodarone) were determined in plasma and tissue samples employing a high-performance liquid chromatography-diode array detection method previously developed and validated. RESULTS In both studies was observed a delay in attaining the maximum plasma concentrations of amiodarone (tmax) in the rats treated with the extract. Nevertheless, it must be highlighted the marked increase (60-70%) of the extent of amiodarone systemic exposure (as assessed by AUC0-t and AUC0-∞) in the rats pre-treated with C. papaya comparatively with the control (vehicle) group. CONCLUSIONS The results herein found suggest an herb-drug interaction between C. papaya extract and amiodarone, which clearly increase the drug bioavailability. To reliably assess the clinical impact of these findings appropriate human studies should be conducted.

[1]  I. Klein,et al.  Amiodarone-Induced Thyroid Dysfunction , 2015, Journal of intensive care medicine.

[2]  P. Anzenbacher,et al.  Administration of a Probiotic Can Change Drug Pharmacokinetics: Effect of E. coli Nissle 1917 on Amidarone Absorption in Rats , 2014, PloS one.

[3]  A. Falcão,et al.  Investigating herb-drug interactions: the effect of Citrus aurantium fruit extract on the pharmacokinetics of amiodarone in rats. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[4]  J. Queiroz,et al.  A rapid HPLC method for the simultaneous determination of amiodarone and its major metabolite in rat plasma and tissues: a useful tool for pharmacokinetic studies. , 2013, Journal of chromatographic science.

[5]  A. Falcão,et al.  Herb-drug interaction of Fucus vesiculosus extract and amiodarone in rats: a potential risk for reduced bioavailability of amiodarone in clinical practice. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[6]  Y. Shitara,et al.  P-glycoprotein mediated efflux in Caco-2 cell monolayers: the influence of herbals on digoxin transport. , 2012, Journal of ethnopharmacology.

[7]  A. Falcão,et al.  Herb-Drug Interaction of Paullinia cupana (Guarana) Seed Extract on the Pharmacokinetics of Amiodarone in Rats , 2012, Evidence-based complementary and alternative medicine : eCAM.

[8]  W. Chatuphonprasert,et al.  Impact of six fruits—banana, guava, mangosteen, pineapple, ripe mango and ripe papaya—on murine hepatic cytochrome P450 activities , 2012, Journal of applied toxicology : JAT.

[9]  B. Amadi,et al.  Toxic effect of carica papaya bark on body weight, haematology, and some biochemical parameters , 2012 .

[10]  Kadry Mohamed Sadek.  ANTIOXIDANT AND IMMUNOSTIMULANT EFFECT OF CARICA PAPAYA LINN. AQUEOUS EXTRACT IN ACRYLAMIDE INTOXICATED RATS , 2012, Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH.

[11]  A. Ibrahimi,et al.  Acute hepatitis secondary to parenteral amiodarone does not preclude subsequent oral therapy. , 2012, World journal of hepatology.

[12]  Z. Ismail,et al.  Repeated Dose 28-Days Oral Toxicity Study of Carica papaya L. Leaf Extract in Sprague Dawley Rats , 2012, Molecules.

[13]  U. Patil,et al.  Effect of ether- and water-soluble fractions of Carica papaya ethanol extract in experimentally induced hyperlipidemia in rats , 2011, Pharmaceutical biology.

[14]  B. Franklin,et al.  Impact of obesity on cardiovascular disease. , 2011, The Medical clinics of North America.

[15]  J. Hamman,et al.  Herb–drug pharmacokinetic interactions reviewed , 2010, Expert opinion on drug metabolism & toxicology.

[16]  S. Karimi,et al.  Results of a Safety Initiative for Patients on Concomitant Amiodarone and Simvastatin Therapy in a Veterans Affairs Medical Center , 2010, Journal of managed care pharmacy : JMCP.

[17]  P. Dorian,et al.  Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia , 2010, Vascular health and risk management.

[18]  E. Roughead,et al.  Prevalence of potentially hazardous drug interactions amongst Australian veterans. , 2010, British journal of clinical pharmacology.

[19]  S. Papiris,et al.  Amiodarone: review of pulmonary effects and toxicity. , 2010, Drug safety.

[20]  D. Brocks,et al.  The effect of beta-naphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes. , 2010, Toxicology letters.

[21]  Stephanie B Edwin,et al.  An Evaluation of the Early Pharmacodynamic Response After Simultaneous Initiation of Warfarin and Amiodarone , 2010, Journal of clinical pharmacology.

[22]  N. K. Lohiya,et al.  Safety evaluation of long term oral treatment of methanol sub-fraction of the seeds of Carica papaya as a male contraceptive in albino rats. , 2010, Journal of ethnopharmacology.

[23]  P. Akah,et al.  Carica papaya (Paw-Paw) unripe fruit may be beneficial in ulcer. , 2009, Journal of medicinal food.

[24]  K. L. Krishna,et al.  Review on nutritional, medicinal and pharmacological properties of Papaya ( Carica papaya Linn.) , 2008 .

[25]  Mohammad Tariqur Rahman,et al.  Effect of green and ripe Carica papaya epicarp extracts on wound healing and during pregnancy. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[26]  J. Donovan,et al.  Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations. , 2008, Molecular nutrition & food research.

[27]  S. Bent,et al.  Herbal Medicine in the United States: Review of Efficacy, Safety, and Regulation , 2008, Journal of General Internal Medicine.

[28]  H. Kai,et al.  Inhibitory Effects of Fruit Juices on Cytochrome P450 2C9 Activity in Vitro , 2008, Bioscience, biotechnology, and biochemistry.

[29]  D. Brocks,et al.  Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone , 2008, Biopharmaceutics & drug disposition.

[30]  G. D'arcangelo,et al.  Gas chromatography–mass spectrometry analysis of phenolic compounds from Carica papaya L. leaf , 2007 .

[31]  P. Bodary,et al.  Strategies to reduce vascular risk associated with obesity. , 2007, Current vascular pharmacology.

[32]  Shufeng Zhou,et al.  Identification of drugs that interact with herbs in drug development. , 2007, Drug discovery today.

[33]  R. Porsche,et al.  Amiodarone-induced thyroid dysfunction. , 2006, Critical care nurse.

[34]  E. Nutescu,et al.  Warfarin and its interactions with foods, herbs and other dietary supplements , 2006, Expert opinion on drug safety.

[35]  S. Strom,et al.  In vitro and in vivo assessment of herb drug interactions. , 2006, Life sciences.

[36]  D. Brocks,et al.  Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat‐meal rat models , 2005, Biopharmaceutics & drug disposition.

[37]  E Ernst,et al.  Adverse events of herbal food supplements for body weight reduction: systematic review * , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[38]  A. Izzo,et al.  Herb–drug interactions: an overview of the clinical evidence , 2005, Fundamental & clinical pharmacology.

[39]  K. Arimori,et al.  Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[40]  G. Licata,et al.  Obesity and cardiovascular risk: the new public health problem of worldwide proportions , 2004, Expert review of cardiovascular therapy.

[41]  L. Siddoway.  Amiodarone: guidelines for use and monitoring. , 2003, American family physician.

[42]  N. Shear,et al.  Drug interactions: Proteins, pumps, and P-450s. , 2002, Journal of the American Academy of Dermatology.

[43]  I Weinryb,et al.  Bioavailability of amiodarone tablets administered with and without food in healthy subjects. , 2001, The American journal of cardiology.

[44]  H. Yamazaki,et al.  A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[45]  J. Calixto,et al.  Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[46]  M. Merino,et al.  INTESTINAL ABSORPTION KINETICS OF AMIODARONE IN RAT SMALL INTESTINE , 1997, Biopharmaceutics & drug disposition.

[47]  V. Casabó,et al.  Effects of Surfactants on Amiodarone Intestinal Absorption. I. Sodium Laurylsulfate , 1994, Pharmaceutical Research.

[48]  Y. Shachor,et al.  [Amiodarone pulmonary toxicity]. , 1985, Harefuah.

[49]  M. Josephson,et al.  Amiodarone pulmonary toxicity. , 1982, Annals of internal medicine.

[50]  G.Harish,et al.  Traditional and Medicinal Uses of Carica papaya , 2013 .

[51]  M. Parat,et al.  Anticancer activity of Carica papaya: a review. , 2013, Molecular nutrition & food research.

[52]  T. Horie,et al.  Ex vivo and in vivo investigations of the effects of extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on digoxin transport and pharmacokinetics: assessing the significance on rat intestinal P-glycoprotein efflux. , 2013, Drug metabolism and pharmacokinetics.

[53]  K. Murugan,et al.  Antimalarial activity of Carica papaya (Family: Caricaceae) leaf extract against Plasmodium falciparum , 2012 .

[54]  P. Brindha,et al.  ANTI-OBESITY EFFECT OF AQUEOUS FRUIT EXTRACT OF CARICA PAPAYA L. IN RATS FED ON HIGH FAT CAFETERIA DIET , 2012 .

[55]  P. Milind.  BASKETFUL BENEFITS OF PAPAYA , 2011 .

[56]  A. Adeneye,et al.  Preliminary hypoglycemic and hypolipidemic activities of the aqueousseed extract of Carica papaya Linn. in Wistar rats , 2009 .

[57]  V. Butterweck,et al.  Potential of Pharmacokinetic Profiling for Detecting Herbal Interactions with Drugs , 2008, Clinical pharmacokinetics.

[58]  Oprs Alert.  Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers , 2005 .

[59]  D. Brocks,et al.  Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. , 2004, Drug metabolism and disposition: the biological fate of chemicals.